

| Set | Items | Description |
|-----|---------|--|
| S1 | 339 | AU="FRANKLIN R" |
| S2 | 7 | AU="FRANKLIN R L" |
| S3 | 1 | AU="FRANKLIN R.F." |
| S4 | 19 | AU="FRANKLIN RICHARD" |
| S5 | 20 | AU="FRANKLIN RICHARD L" OR AU="FRANKLIN RL" |
| S6 | 41 | AU="DE FAIRE J" OR AU="DE FAIRE J R" OR AU="DE FAIRE JOHAN" OR AU="DE FAIRE JOHAN R" |
| S7 | 73 | AU="KAY JOHN" |
| S8 | 33343 | AU="LINDBLOM R" OR AU="LINDBLOM R E" OR AU="LINDBLOM RAGNU- ALD ERIK" OR D9 OR AU="LINDBLOM RAGNVALD E" OR AU="LINDBLOM R- AGNVALD ERIK" |
| S9 | 86 | AU="LINDBLOM R" OR AU="LINDBLOM R." OR AU="LINDBLOM R E" OR AU="LINDBLOM RAGNUALD ERIK" OR AU="LINDBLOM RAGNVALD" OR AU=- "LINDBLOM RAGNVALD E" OR AU="LINDBLOM RAGNVALD ERIK" |
| S10 | 541 | S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S9 |
| S11 | 7464 | KRILL |
| S12 | 4336774 | ENZYME? ? |
| S13 | 480 | S11(S)S12 |
| S14 | 305 | S13 NOT PY>1995 |
| S15 | 211 | RD (unique items) |
| S16 | 4 | S10 AND S15 |
| S17 | 1355792 | DENTAL OR TOOTH OR TEETH OR PLAQUE |
| S18 | 47 | S13 AND S17 |
| S19 | 19 | S18 NOT PY>1995 |
| S20 | 19 | RD (unique items) |
| ? | | |

16/3,AB/1 (Item 1 from file: 342)
DIALOG(R) File 342:Derwent Patents Citation Indx
(c) 2001 Derwent Info Ltd. All rts. reserv.

02210193 WPI Acc No: 95-206781/27

Mixt. of enzymes from Antarctica krill and salt complexing cpds. - for
treatment of inflammation, cancer, wounds and microbial-induced infections

Patent Assignee: (PHAI-) PHAIRSON MEDICAL INC

Author (Inventor): DE FAIRE J ; LINDBLOM R ; ARFORS K

Patent (basic)

| Patent No | Kind | Date | Examiner | Field of Search |
|------------|------|--------|----------|-----------------|
| WO 9514489 | A1 | 950601 | (BASIC) | A61K |

Derwent Week (Basic): 9527

Priority Data: SE 933899 (931122)

Applications: WO 94SE1112 (941122); AU 9510821 (941122)

Designated States

(National): AM; AT; AU; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; EE; ES;
FI; GB; GE; HU; JP; KE; KG; KP; KR; KZ; LK; LT; LU; LV; MD; MG; MN; MW
; NL; NO; NZ; PL; PT; RO; RU; SD; SE; SI; SK; TJ; TT; UA; US; UZ; VN

(Regional): AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; KE; LU; MC; MW;
NL; OA; PT; SD; SE; SZ

Derwent Class: B04; D16

Int Pat Class: A61K-035/60

Number of Patents: 002

Number of Countries: 058

Number of Cited Patents: 012

Number of Cited Literature References: 014

Number of Citing Patents: 000

16/3,AB/2 (Item 1 from file: 348)
DIALOG(R) File 348:EUROPEAN PATENTS
(c) 2001 European Patent Office. All rts. reserv.

00610612

NEW PHARMACEUTICAL USES OF KRILL ENZYMES.

NEUARTIGE PHARMAZEUTISCHE VERWENDUNGEN VON KRILL- ENZYMEN.

NOUVELLES UTILISATIONS PHARMACEUTIQUES DES ENZYMES DU KRILL.

PATENT ASSIGNEE:

PHAIRSON MEDICAL AB, (1736330), Bruksforvaltarvagen 18, S-74033 Vattholma
, (SE), (applicant designated states:

AT;BE;CH;DE;DK;ES;FR;GB;GR;IE;IT;LI;LU;MC;NL;PT;SE)

INVENTOR:

LINDBLOM, Ragnvald , Alsater, S-740 10 Almunge, (SE)

DE FAIRE, Johan , Bruksforvaltarvagen 18, S-740 33 Vattholma, (SE)

LEGAL REPRESENTATIVE:

Lunt, Mark George Francis et al (50466), Dibb Lupton Alsop Fountain
Precinct Balm Green, Sheffield S1 1RZ, (GB)

PATENT (CC, No, Kind, Date): EP 642351 A1 950315 (Basic)
WO 9324142 931209

APPLICATION (CC, No, Date): EP 93910549 930521; WO 93SE455 930521

PRIORITY (CC, No, Date): SE 921628 920522

DESIGNATED STATES: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LI; LU; MC;
NL; PT; SE

INTERNATIONAL PATENT CLASS: A61K-037/54; C12N-009/50;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English

16/3,AB/3 (Item 1 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00383817

COMPOSITION COMPRISING COMPOUNDS FOR USE AS THERAPEUTICAL AGENT
COMPOSITION COMPRENANT DES COMPOSES UTILISES COMME AGENT THERAPEUTIQUE

Patent Applicant/Assignee:

PHAIRSON MEDICAL INC
DE FAIRE Johan
LINDBLOM Ragnvald
ARFORS Karl-Erik

Inventor(s):

DE FAIRE Johan
LINDBLOM Ragnvald
ARFORS Karl-Erik

Patent and Priority Information (Country, Number, Date):

Patent: WO 9514489 A1 19950601
Application: WO 94SE1112 19941122 (PCT/WO SE9401112)
Priority Application: SE 933899 19931122

Designated States: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU
JP KE KG KP KR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ
TT UA US UZ VN SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 7952

English Abstract

The invention relates to a composition comprising non-immunogenic exo- and endopeptidase **enzymes** isolated from Antarctic **krill** Euphasia superba and salt complexing compounds for use as therapeutical agents.

French Abstract

L'invention porte sur une composition comprenant des **enzymes** non immunogenes du type exo et endopeptidases isolees a partir du **krill** Euphasia superba de l'antarctique et des composes de complexant des sels utilisables comme agents therapeutiques.

16/3,AB/4 (Item 2 from file: 349)
DIALOG(R)File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00339288

NEW PHARMACEUTICAL USES OF KRILL ENZYMES
NOUVELLES UTILISATIONS PHARMACEUTIQUES DES ENZYMES DU KRILL

Patent Applicant/Assignee:

PHAIRSON MEDICAL AB
LINDBLOM Ragnvald
DE FAIRE Johan

Inventor(s):

LINDBLOM Ragnvald
DE FAIRE Johan

Patent and Priority Information (Country, Number, Date):

Patent: WO 9324142 A1 19931209
Application: WO 93SE455 19930521 (PCT/WO SE9300455)
Priority Application: SE 921628 19920522

Designated States: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK
LU MG MN MW NL PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR
IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

DIALOG

Fulltext Word Count: 16944

English Abstract

Non-immunogenic **enzyme** compositions which have been isolated from antarctic **krill** and exhibit both endo- and exo-peptidase activity, are useful for the manufacture of medicaments and pharmaceutical compositions for the treatment of a great variety of diseases in humans and animals such as infections, inflammations, cancers, HIV/AIDS, pain, polyps, warts, hemorrhoids, plaque, wrinkles, thin hair, allergic itch, anti-adhesion, eye diseases such as cataract, glaucom, etc.

French Abstract

L'invention se rapporte a des compositions enzymatiques non immunogenes, qui ont ete isolees du krill de l'Antarctique et qui possedent une activite a la fois d'endopeptidase et d'exopeptidase. Ces compositions servent a la fabrication de medicaments et de compositions pharmaceutiques pour le traitement d'une grande variete de maladies chez l'homme et chez les animaux, telles que les infections, les inflammations, les cancers, l'infection a VIH et le SIDA, les douleurs, les polypes, les verrues, les hemorroïdes, la plaque, les rides, la rarefaction des cheveux, les demangeaisons d'origine allergique, l'antiadhesion, les maladies des yeux telles que la cataracte, le glaucome, etc..

?

DIALOG

20/3,AB/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

03664938 BIOSIS NO.: 000074080515

FEEDING KRILL EUPHAUSIA-SUPERBA TO RATS WITH SPECIAL REGARD TO FLUORIDE
AUTHOR: SIEBERT G; GABRIEL E; HANNOVER R; HENSCHLER D; KARLE E J; KASPER H;
MACK M; ROMEN W; SCHMAUCK B; TRAUTNER K
AUTHOR ADDRESS: ABT. F. EXPERIMENTELLE ZAHNHEIKUNDE, UNIV. WUERZBURG,
PLEICHERWALL 2, 8700, WUERZBURG.
JOURNAL: ARCH FISCHEREIWISS 32 (1-3). 1982. 43-58. 1982
FULL JOURNAL NAME: Archiv fuer Fischereiwissenschaft
CODEN: AVFSA
RECORD TYPE: Abstract
LANGUAGE: GERMAN

ABSTRACT: Freeze-dried krill meat was given to young growing rats and compared with fish flour and shrimp flour in a 90-day feeding experiment. Animals on krill ration received about 200 mg fluoride during the experiment. The krill containing diet had the same effect on growth rate as other sources of protein but produced alterations in organ weight and plasma enzymes which are regarded as abnormal. A causal connection between these alterations and the high uptake of fluoride is not definitely established. Changes in teeth and large bones typical for fluoride were observed and corroborated by chemical analyses. According to determinations of fluoride in urine and feces, fluoride in krill is well utilized. Disturbances in mineralization are causally connected with the administration of fluoride. Minced krill meat cannot be recommended for human consumption beyond a daily uptake of 1-2 g of dry materials, a negligible amount in nutrient supply.

1982

20/3,AB/2 (Item 1 from file: 98)
DIALOG(R)File 98:General Sci Abs/Full-Text
(c) 2001 The HW Wilson Co. All rts. reserv.

03029672 H.W. WILSON RECORD NUMBER: BGSA95029672

The secret lives of krill.

Stevens, Jane E

Sea Frontiers v. 41 (Summer 1995) p. 26-31

SPECIAL FEATURES: il ISSN: 0897-2249

LANGUAGE: English

COUNTRY OF PUBLICATION: United States

WORD COUNT: 3835

ABSTRACT: While researchers still have much to learn about krill, knowledge about the small, shrimp-like crustacean is increasing all the time. The article discusses the Antarctic krill (*Euphausia superba*) and its importance to the Antarctic ecosystem, limits imposed by the Commission for the Conservation of Antarctic Marine Living Resources on krill harvesting, the nature of krill swarms, the life cycle of krill, the fecundity of female krill, how krill inhabit Antarctic sea ice, krill characteristics that baffle scientists, and why krill can be unfit for human consumption.

20/3,AB/3 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

DIALOG

124126932 CA: 124(10)126932c PATENT

Composition for dental use comprising krill enzymes

INVENTOR(AUTHOR): Hellgren, Kristian; Hellgren, Lars; Mohr, Viggo;
Vincent, Jan

LOCATION: Swed.

PATENT: PCT International ; WO 9533470 A1 DATE: 951214

APPLICATION: WO 94SE549 (940607)

PAGES: 15 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-035/60A;

A61K-038/55B DESIGNATED COUNTRIES: AT; AU; BB; BG; BR; BY; CA; CH; CN; CZ;
DE; DK; ES; FI; GB; GE; HU; JP; KG; KP; KR; KZ; LK; LU; LV; MD; MG; MN; MW;
NL; NO; NZ; PL; PT; RO; RU; SD; SE; SK; TJ; TT; UA; US; UZ; VN

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

20/3,AB/4 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

120095821 CA: 120(9)95821b PATENT

Pharmaceutical uses of krill enzymes

INVENTOR(AUTHOR): Lindblom, Ragnvald; De, Faire Johan

LOCATION: Swed.

ASSIGNEE: Phairson Medical AB

PATENT: PCT International ; WO 9324142 A1 DATE: 931209

APPLICATION: WO 93SE455 (930521) *SE 921628 (920522)

PAGES: 77 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-037/54A;

C12N-009/50B DESIGNATED COUNTRIES: AT; AU; BB; BG; BR; CA; CH; CZ; DE; DK;
ES; FI; GB; HU; JP; KP; KR; KZ; LK; LU; MG; MN; MW; NL; NO; NZ; PL; PT; RO;
RU; SD; SE; SK; UA; US; VN DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR
; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML;
MR; NE; SN; TD; TG

20/3,AB/5 (Item 1 from file: 348)

DIALOG(R)File 348:EUROPEAN PATENTS

(c) 2001 European Patent Office. All rts. reserv.

00277338

An enzyme preparation capable of degrading glycosaminoglycan, and a method
for producing said preparation.

Zum Abbau von Glycosaminoglycan fahige Enzymzusammensetzung und Verfahren
zur Herstellung dieser Zusammensetzung.

Composition d'enzyme capable de degrader le glycosaminoglycane, et methode
de production de cette composition.

PATENT ASSIGNEE:

Kabi Pharmacia AB, (441372), Rapskatan 7, S-751 82 Uppsala, (SE),

(applicant designated states: AT;BE;CH;DE;ES;FR;GB;GR;IT;LI;LU;NL;SE)

INVENTOR:

Karlstam, Bjorn E.O., Spiltvagen 7, S-740 30 Bjorklinge, (SE)

PATENT (CC, No, Kind, Date): EP 257003 A2 880224 (Basic)

EP 257003 A3 900228

EP 257003 B1 931013

APPLICATION (CC, No, Date): EP 87850203 870622;

PRIORITY (CC, No, Date): SE 863051 860709

DESIGNATED STATES: AT; BE; CH; DE; ES; FR; GB; GR; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C12N-009/26; A61K-037/54

ABSTRACT EP 257003 A2

Glycosaminoglycan-degrading enzyme preparation containing krill
hyaluronidase, and a method of producing said preparation.

DIALOG

ABSTRACT WORD COUNT: 17

LANGUAGE (Publication,Procedural,Application): English; English; English
FULLTEXT AVAILABILITY:

| Available Text | Language | Update | Word Count |
|------------------------------------|-----------|--------|------------|
| CLAIMS B | (English) | EPBBF1 | 147 |
| CLAIMS B | (German) | EPBBF1 | 223 |
| CLAIMS B | (French) | EPBBF1 | 262 |
| SPEC B | (English) | EPBBF1 | 3504 |
| Total word count - document A | | | 0 |
| Total word count - document B | | | 4136 |
| Total word count - documents A + B | | | 4136 |

20/3,AB/6 (Item 1 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00402569

COMPOSITION FOR DENTAL USE COMPRISING KRILL ENZYME
COMPOSITION A USAGE DENTAIRE COMPRENANT UNE ENZYME DE KRILL

Patent Applicant/Assignee:

HELLGREN Kristian
HELLGREN Lars
MOHR Viggo
VINCENT Jan

Inventor(s):

HELLGREN Kristian
HELLGREN Lars
MOHR Viggo
VINCENT Jan

Patent and Priority Information (Country, Number, Date):

Patent: WO 9533470 A1 19951214
Application: WO 94SE549 19940607 (PCT/WO SE9400549)
Priority Application: WO 94SE549 19940607

Designated States: AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG
KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK TJ TT UA US UZ VN
AT BE CH DE DK GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR
NE SN TD TG

Publication Language: English

Fulltext Word Count: 2240

English Abstract

Krill enzymes are used for the manufacture of a prophylactic composition for preventing **dental plaque** formation in a human subject, in particular for manufacture of a composition for decreasing the adhesive ability of **plaque** bacteria. A method for preventing **dental plaque** formation in a human subject and a method for decreasing the adhesive ability of **plaque** bacteria comprise administering such composition in the oral cavity of said subject.

French Abstract

On utilise des **enzymes** de **krill** pour fabriquer une composition prophylactique destinee a prevenir la formation de la **plaque** dentaire chez un sujet humain, en particulier pour fabriquer une composition destinee a reduire l'adherence des bacteries de la **plaque**. Une methode de prevention de la formation de la **plaque** dentaire chez un sujet humain, et une methode de reduction de l'adherence des bacteries de la **plaque** consistent a administrer ladite composition dans la cavite buccale dudit sujet.

DIALOG

20/3,AB/7 (Item 2 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00339288

NEW PHARMACEUTICAL USES OF KRILL ENZYMES
NOUVELLES UTILISATIONS PHARMACEUTIQUES DES ENZYMES DU KRILL

Patent Applicant/Assignee:

PHAIRSON MEDICAL AB

LINDBLOM Ragnvald

DE FAIRE Johan

Inventor(s):

LINDBLOM Ragnvald

DE FAIRE Johan

Patent and Priority Information (Country, Number, Date):

Patent: WO 9324142 A1 19931209

Application: WO 93SE455 19930521 (PCT/WO SE9300455)

Priority Application: SE 921628 19920522

Designated States: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK
LU MG MN MW NL PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR
IE IT LU MC NL BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 16944

English Abstract

Non-immunogenic **enzyme** compositions which have been isolated from antarctic **krill** and exhibit both endo- and exo-peptidase activity, are useful for the manufacture of medicaments and pharmaceutical compositions for the treatment of a great variety of diseases in humans and animals such as infections, inflammations, cancers, HIV/AIDS, pain, polyps, warts, hemorrhoids, **plaque**, wrinkles, thin hair, allergic itch, anti-adhesion, eye diseases such as cataract, glaucom, etc.

French Abstract

L'invention se rapporte a des compositions enzymatiques non immunogenes, qui ont ete isolees du krill de l'Antarctique et qui possedent une activite a la fois d'endopeptidase et d'exopeptidase. Ces compositions servent a la fabrication de medicaments et de compositions pharmaceutiques pour le traitement d'une grande variete de maladies chez l'homme et chez les animaux, telles que les infections, les inflammations, les cancers, l'infection a VIH et le SIDA, les douleurs, les polypes, les verrues, les hemorroides, la **plaque**, les rides, la rarefaction des cheveux, les demangeaisons d'origine allergique, l'antiadhesion, les maladies des yeux telles que la cataracte, le glaucome, etc..

20/3,AB/9 (Item 4 from file: 349)
DIALOG(R) File 349:PCT Fulltext
(c) 2001 WIPO/MicroPat. All rts. reserv.

00206463

ENZYME COMPOSITION FOR THERAPEUTICAL AND/OR NON-THERAPEUTICAL CLEANING, THE USE THEREOF AND PREPARATION OF THE COMPOSITION
COMPOSITION ENZYMATIQUE POUR NETTOYAGE THERAPEUTIQUE ET/OU NON THERAPEUTIQUE, UTILISATION ET PREPARATION DE LA COMPOSITION

Patent Applicant/Assignee:

HELLGREN Lars Gustav Inge

MOHR Viggo

VINCENT Jan Gustav

DIALOG

Inventor(s):

HELLGREN Lars Gustav Inge
MOHR Viggo
VINCENT Jan Gustav

Patent and Priority Information (Country, Number, Date):

Patent: WO 8401715 A1 19840510
Application: WO 83SE359 19831024 (PCT/WO SE8300359)
Priority Application: SE 826022 19821025; SE 832268 19830422

Designated States: AU BR DK FI HU JP NO RO SU US

Publication Language: English

Fulltext Word Count: 6861

English Abstract

An enzyme composition, containing an effective amount of an enzyme preparation which degrades contaminants of biological origin, for use as a therapeutical and/or non-therapeutical agent, a method for its preparation and a method for the therapeutical and non-therapeutical cleaning of living and dead material. The enzyme preparation used is derived from an aquatic animal of the order Euphausiacea or from a fish. Among fishes those of the genus *Mallotus* are preferred.

French Abstract

Une composition enzymatique contenant une quantite efficace d'une preparation enzymatique degradant des substances contaminantes d'origine biologique, utilisable comme agent de nettoyage therapeutique et/ou non therapeutique, son procede de preparation et un procede de nettoyage therapeutique et non therapeutique de materiau vivant et mort. La preparation enzymatique utilisee est derivee d'un animal aquatique appartenant a l'ordre des Euphausiacea ou d'un poisson. En ce qui concerne ces derniers, on prefere les poissons de l'espece *Mallotus*.

20/3,AB/10 (Item 1 from file: 653)

DIALOG(R) File 653:US Patents Fulltext

(c) format only 2001 The Dialog Corp. All rts. reserv.

01758521

Utility

PROCESS FOR PREPARING PASTY PROTEINOUS MATERIAL OR PROTEINOUS FOOD FROM CRUSTACEANS
[HEATING RESIDUES TO INACTIVATE ENZYMES, MILLING, TREATING WITH PROTEOLYTIC ENZYMES OR MICROORGANISMS]

PATENT NO.: 4,820,529

ISSUED: April 11, 1989 (19890411)

INVENTOR(s): Uchida, Yasuzo, Tokyo, JP (Japan)
Nagasaki, Hitoshi, Tokyo, JP (Japan)
Itoh, Makoto, Tokyo, JP (Japan)

ASSIGNEE(s): Asahi Denka Kogyo Kabushiki Kaisha, (A Non-U.S. Company or Corporation), Tokyo, JP (Japan)
[Assignee Code(s): 5584]

APPL. NO.: 7-65,264

FILED: June 22, 1987 (19870622)

PRIORITY: 61-149994, JP (Japan), June 26, 1986 (19860626)
62-113306, JP (Japan), May 8, 1987 (19870508)

FULL TEXT: 1819 lines

ABSTRACT

According to the process of the present invention for preparing a pasty proteinous material or a proteinous food, crustaceans are boiled and milled

DIALOG

under sufficient conditions for inactivating enzymes contained therein and then proteolytic enzyme(s) and/or micro-organism(s) are allowed to act thereon. Thus various protein sources including crustacean meat remaining in the trunks and carapaces, which have been disposed hitherto, can be efficiently utilized.

20/3,AB/12 (Item 3 from file: 653)
DIALOG(R) File 653:US Patents Fulltext
(c) format only 2001 The Dialog Corp. All rts. reserv.

01738207

Utility
CLEANING WITH **ENZYMES** FROM KRILL
[ENZYMATIC DEBRIDEMENT OF LIVING TISSUES]

PATENT NO.: 4,801,451
ISSUED: January 31, 1989 (19890131)
INVENTOR(s): Hellgren, Lars G. I., Bronsgjutargatan 13, S-421 63 V:a
Frolunda, SE (Sweden)
Mohr, Viggo, St. Jorgensveita 6a, N-7000 Trondheim, NO
(Norway)
Vincent, Jan G., Linnegatan 31, S-114 47 Stockholm, SE
(Sweden)
[Assignee Code(s): 68000]
EXTRA INFO: Assignment transaction [Reassigned], recorded June 12,
1996 (19960612)
APPL. NO.: 7-82,134
FILED: August 06, 1987 (19870806)

This application is a continuation of application Ser. No. 621,911, filed June 18, 1984, now abandoned.

FULL TEXT: 569 lines

ABSTRACT

Enzymes from animals belonging to the order Euphausiacea are used for cleaning. Preferably, an **enzyme** mixture containing exo-and endopeptidases from **krill** are used. Living tissue can be cleaned or debrided with the **enzyme** mixture, isolation of the **enzymes** may be carried out by homogenizing **krill** and extracting with an aqueous medium. Further purification can be by gel chromatography. **Enzymes** from which lipids have been extracted may be lyophilized for long time storage.

20/3,AB/13 (Item 1 from file: 654)
DIALOG(R) File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

02124508

Utility
TRANSGULTAMINASE
[Derived from microorganism; catalyzes protein gelation in absence of calcium]

PATENT NO.: 5,156,956
ISSUED: October 20, 1992 (19921020)
INVENTOR(s): Motoki, Masao, Kawasaki, JP (Japan)
Okuyama, Atsushi, Kawasaki, JP (Japan)

DIALOG

Nonaka, Masahiko, Kawasaki, JP (Japan)
Tanaka, Haruo, Kawasaki, JP (Japan)
Uchio, Ryosuke, Kawasaki, JP (Japan)
Matsuura, Akira, Kasugai, JP (Japan)
Ando, Hiroyasu, Konan, JP (Japan)
Umeda, Koichi, Gifu, JP (Japan)
ASSIGNEE(s): Ajinomoto Co Inc , (A Non-U.S. Company or Corporation),
Tokyo, JP (Japan)
Amano Pharmaceutical Co Ltd , (A Non-U.S. Company or
Corporation), Nagoya, JP (Japan)
[Assignee Code(s): 1352; 2527]
APPL. NO.: 7-726,722
FILED: July 01, 1991 (19910701)
PRIORITY: 62-049157, JP (Japan), March 4, 1987 (19870304)
62-165067, JP (Japan), July 1, 1987 (19870701)

This application is a continuation of application Ser. No. 07-162,988,
filed on Mar. 2, 1988, now abandoned.

FULL TEXT: 1083 lines

ABSTRACT

A transglutaminase catalyzing an acyl transfer reaction of a gamma
-carboxyamide group of a glutamine residue in a peptide or protein chain in
the absence of Ca sup 2+.

20/3,AB/17 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

01913326

Utility

PROCESS OF REMOVING BIOLOGICAL CONTAMINANTS WITH **ENZYMES** FROM **KRILL**
[APPLYING ISOLATED MIXTURE OF EXO-AND ENDOPEPTIDASES]

PATENT NO.: 4,963,491
ISSUED: October 16, 1990 (19901016)
INVENTOR(s): Hellgren, Lars G. I., Vastra Frolunda, S-421 63 V:a Frolunda,
SE (Sweden)
Mohr, Viggo, St. Jorgensveita 6a, N-7000 Trondheim, NO
(Norway)
Vincent, Jan G., Linnegatan 31, S-114 47 Stockholm, SE
(Sweden)
[Assignee Code(s): 68000]
EXTRA INFO: Assignment transaction [Reassigned], recorded June 12,
1996 (19960612)
APPL. NO.: 7-302,190
FILED: January 27, 1989 (19890127)
DISCLAIMER: January 31, 2006 (20060131)
PRIORITY: 8206022, SE (Sweden), October 25, 1982 (19821025)
83022681, SE (Sweden), April 22, 1983 (19830422)

This application is a division of application Ser. No. 082,134 filed Aug.
6, 1987, now U.S. Pat. No. 4,801,451, which in turn is a continuation of
application Ser. No. 621,911 filed June 18, 1984, now abandoned.

FULL TEXT: 589 lines

ABSTRACT

Enzymes isolated from **krill** of the order Euphausiacea are used to remove biological contaminants. Preferably, a mixture of **enzymes** including exo- and endopeptidase is isolated. The **enzymes** can be used in laundering or to clean or debride living tissue. Isolation may be carried out by homogenizing **krill** and extracting the **enzymes** with an aqueous medium. The **enzymes** may be further purified by gel chromatography. After lipids have been removed, the **enzymes** can be lyophilized for long time storage.

20/3,AB/19 (Item 7 from file: 654)
DIALOG(R) File 654:US Pat.Full.
(c) format only 2001 The Dialog Corp. All rts. reserv.

01848987

Utility

ENZYME PREPARATION CAPABLE OF DEGRADING GLYCOSAMINO-GLYCAN, AND A METHOD FOR PRODUCING SAID PREPARATION

PATENT NO.: 4,904,594
ISSUED: February 27, 1990 (19900227)
INVENTOR(s): Karlstam, Bjorn O. E., Bjorklinge, SE (Sweden)
ASSIGNEE(s): Pharmacia AB, (A Non-U.S. Company or Corporation), Uppsala, SE (Sweden)
[Assignee Code(s): 65439]
EXTRA INFO: Assignment transaction [Reassigned], recorded April 16, 1996 (19960416)
Assignment transaction [Reassigned], recorded February 5, 1997 (19970205)
APPL. NO.: 7-65,591
FILED: June 23, 1987 (19870623)
PRIORITY: 8603051, SE (Sweden), July 9, 1986 (19860709)

FULL TEXT: 414 lines

ABSTRACT

Glycosaminoglycan-degrading **enzyme** preparation containing **krill** hyaluronidase, and a method of producing said preparation.

?